^
Association details:
| Biomarker: | BRAF D594G |
|---|---|
| Cancer: | Ampulla of Vater Carcinoma |
| Drug: | Mektovi (binimetinib) (MEK inhibitor) + Braftovi (encorafenib) (BRAF inhibitor, cRAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
531P - Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations (mts): Preliminary results of the investigator initiated phase II BEAVER trial
Published date:
09/13/2021
Excerpt:
ORR was 22% (2/9) with a confirmed PR in a pt with ampullary cancer (BRAF D594G, class 3) who continues on treatment for 5.4+ months, and an unconfirmed PR in a melanoma pt (BRAF G469S, class 2) treated for 6.5 months. One gallbladder cancer pt (BRAF D594N, class 3) had SD, treated for 4.4 months....Preliminary data confirmed the safety of B+E and demonstrated evidence of anti-tumor activity in advanced cancer pts with non-V600E BRAF mts.
